Legato Capital Management LLC bought a new stake in Clovis Oncology, Inc. (NASDAQ:CLVS) during the second quarter, according to its most recent filing with the SEC. The fund bought 2,346 shares of the biopharmaceutical company’s stock, valued at approximately $220,000.
Other large investors also recently bought and sold shares of the company. Renaissance Technologies LLC bought a new stake in Clovis Oncology during the fourth quarter valued at approximately $3,647,000. Guggenheim Capital LLC bought a new stake in Clovis Oncology during the fourth quarter valued at approximately $2,824,000. Ladenburg Thalmann Financial Services Inc. boosted its stake in Clovis Oncology by 20.0% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,400 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 400 shares in the last quarter. Norges Bank bought a new stake in Clovis Oncology during the fourth quarter valued at approximately $13,155,000. Finally, Teachers Advisors LLC boosted its stake in Clovis Oncology by 153.9% in the fourth quarter. Teachers Advisors LLC now owns 420,512 shares of the biopharmaceutical company’s stock valued at $18,679,000 after buying an additional 254,898 shares in the last quarter. 90.01% of the stock is owned by hedge funds and other institutional investors.
Shares of Clovis Oncology, Inc. (NASDAQ CLVS) traded up 1.41% during trading on Friday, hitting $78.52. 812,376 shares of the company traded hands. Clovis Oncology, Inc. has a 52-week low of $14.62 and a 52-week high of $99.45. The stock’s market capitalization is $3.50 billion. The company has a 50-day moving average of $87.51 and a 200-day moving average of $66.24.
Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.27) by $0.02. The business had revenue of $14.62 million during the quarter, compared to the consensus estimate of $13.07 million. During the same period in the prior year, the company posted ($2.07) EPS. The company’s revenue was down 32.5% compared to the same quarter last year. Equities analysts expect that Clovis Oncology, Inc. will post ($5.96) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://stocknewstimes.com/2017/08/04/legato-capital-management-llc-invests-220000-in-clovis-oncology-inc-clvs-updated.html.
A number of research analysts recently issued reports on the stock. Credit Suisse Group reissued an “outperform” rating and set a $74.00 price target on shares of Clovis Oncology in a research report on Tuesday, April 18th. Cann began coverage on shares of Clovis Oncology in a research note on Thursday, June 22nd. They set a “market perform” rating for the company. Bank of America Corporation restated a “buy” rating on shares of Clovis Oncology in a research note on Thursday. BidaskClub upgraded shares of Clovis Oncology from a “hold” rating to a “buy” rating in a research note on Wednesday, June 21st. Finally, Zacks Investment Research lowered shares of Clovis Oncology from a “buy” rating to a “hold” rating in a research note on Thursday, July 13th. Eight analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $81.59.
In other Clovis Oncology news, insider Gillian C. Ivers-Read sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $61.82, for a total value of $185,460.00. Following the completion of the sale, the insider now owns 200,583 shares in the company, valued at $12,400,041.06. The sale was disclosed in a document filed with the SEC, which is available through this link. In the last quarter, insiders sold 9,000 shares of company stock valued at $602,310. 17.40% of the stock is owned by company insiders.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
